Article

EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma

2020-05-12

Abstract excerpt

<title>Abstract</title> <p>Background: Immune checkpoint inhibitor (ICI ) therapy has shown remarkable clinical benefit in lung adenocarcinoma (LUAD) patients. Genomic mutations may be applicable to predict the response to ICIs. Eph receptor A5 (EPHA5) is frequently mutated in breast cancer, lung cancer and other tumors; however, its association with outcome in patients who receive immunotherapy remains unknown....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f5776fc3-cce3-5051-b2bc-894b3f4ee984
DOI: 10.21203/rs.3.rs-27361/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinomaDOI 10.21203/rs.3.rs-27361/v1Read

EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma.Semantic proximity Read

EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.Semantic proximity Read

EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.Semantic proximity Read

The role of EPHA3 mutation in the prognosis of non-small cell lung cancer patients receiving immunotherapySemantic proximity Read

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint InhibitorsSemantic proximity Read

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma.Semantic proximity Read

Prediction of the Potential Efficacy of Dlx5 in Immunotherapy for Hypopharyngeal Cancer through Integrated Bulk and Single-Cell RNA SequencingSemantic proximity Read

A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and PrognosisSemantic proximity Read

BIRC5 expression correlated with immunosuppressive phenotype and predicted inferior response to immunotherapy in lung adenocarcinomaSemantic proximity Read

COL22A1 and DNAH8 mutations are associated with tumor mutation burden and prognosis of lung adenocarcinoma patientsSemantic proximity Read

Systematic Pan-Cancer Analysis Reveals the Prognostic Value and Immunological Role of EPHX2Semantic proximity Read

Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC.Semantic proximity Read